Antimicrobial

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance

MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces...

New Study Demonstrates Potential for Enhanced Accuracy of Blood Cultures with Steripath® Initial Specimen Diversion Device® (ISDD®) for Central Line Draws

SEATTLE, March 5, 2025 /PRNewswire/ -- Magnolia Medical Technologies, Inc., the pioneer in Initial Specimen Diversion Device® (ISDD®) technology, today...

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety...

EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology

SALT LAKE CITY, Jan. 30, 2025 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life,...

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data...

error: Content is protected !!